Learn More
Invitrogen™ Phospho-ERK1/2 (Thr202, Tyr204) Monoclonal Antibody (MILAN8R), Alexa Fluor™ 488, eBioscience™, Invitrogen™

Description
Description: This MILAN8R monoclonal antibody recognizes human and mouse extracellular signal-regulated kinases 1 and 2 (also known as ERK1/2, p44/p42, or MAPK3/1) when phosphorylated on T202/Y204. ERK1/2 belong to a family of conserved serine/threonine protein kinases known as mitogen-activated protein kinases (MAPKs) that are involved in many cellular programs such as proliferation, differentiation, motility, and survival. ERK1/2 signaling is activated in response to numerous extracellular stimuli including mitogens, growth factors, and cytokines. The primary activators of ERK1/2 are MEK1 and MEK2 which act by phosphorylating the activation loop residues T202/Y204 and T185/Y187 in ERK1 and ERK2, respectively. Several downstream targets of ERK1/2 have been identified, including p90RSK and the transcription factor Elk-1. ERK1/2 are negatively regulated by MAPK phosphatases, known as DUSPs or MKPs, as well as by chemical inhibitors of MEK including U0126 and PD98059. Disruption of the ERK pathway is common in many types of cancer. Specificity of this MILAN8R clone was determined by ELISA, flow cytometry, and western blotting. Applications Reported: This MILAN8R antibody has been reported for use in intracellular staining followed by flow cytometric analysis. Applications Tested: This MILAN8R antibody has been tested by intracellular staining followed by flow cytometric analysis of normal human peripheral blood cells. This can be used at less than or equal to 0.
Specifications
Specifications
| Antigen | Phospho-ERK1/2 (Thr202, Tyr204) |
| Applications | Flow Cytometry |
| Classification | Monoclonal |
| Clone | MILAN8R |
| Concentration | 5 μL/Test |
| Conjugate | Alexa Fluor 488 |
| Formulation | PBS with BSA and 0.09% sodium azide; pH 7.2 |
| Gene | MAPK1 |
| Gene Accession No. | P27361, P28482, P63085, Q63844 |
| Gene Alias | 12559; 9030612K14Rik; AA407128; AU018647; BcDNA:RE08694; C78273; CG12559; CG12559-PA; CG12559-PC; CG12559-PD; CG12559-PE; CG12559-PG; CG12559-PH; CG12559-PI; CG18732; CT34260; CT39192; DERK; D-ERK; DERK-A; Diphospho-ERK; dm-dpERK; Dmel\CG12559; Dmel_CG12559; DmErk; DmERKA; DmERK-A; DmMAPK; dpERK; dp-ERK; dpERK1; dpMAPK; drosophila ERK; Dsor2; E(sina)7; EC2-1; EK2-1; enhancer of seven in absentia 7; ERK; Erk MAP kinase; Erk/Map kinase; ERK/rolled; Erk1; Erk-1; erk1 erk2; Erk1/2; ERK1b; ERK2; ERK-2; ERKA; ERK-A; ERT1; ERT2; Esrk1; extracellular signal-regulated kinase; extracellular signal-regulated kinase (ERK2); extracellular signal-regulated kinase 1; Extracellular signal-regulated kinase 2; extracellular signal-regulated kinase A; extracellular signal-regulated kinase-1; extracellular signal-regulated kinase-2; extracellular signal-related kinase 1; Extracellular-regulated kinase A; extracellular-signal-regulated kinase 2; Extracellular-signal-related kinase A; EY2-2; fi06b09; GroupII; HS44KDAP; HUMKER1A; I79_009500; I79_018350; insulin-stimulated MAP2 kinase; l(2)41Ac; l(2R)EMS45-39; M phase MAP kinase; MAP kinase; MAP kinase 1; MAP kinase 2; MAP kinase 3; MAP kinase isoform p42; MAP kinase isoform p44; MapK; MAP-k; MAPK 1; MAPK 2; MAPK 3; MAPK1; mapk1.S; mapk1a; mapk1-a; mapk1-b; mapk2; mapk3; MAP-kinase; MBP kinase; Microtubule-associated protein 2 kinase; mitogen activated protein kinase; mitogen activated protein kinase 1; mitogen activated protein kinase 3; mitogen-activated 3; mitogen-activated protein kinase; mitogen-activated protein kinase 1; mitogen-activated protein kinase 1 S homeolog; mitogen-activated protein kinase 1a; mitogen-activated protein kinase 2; Mitogen-activated protein kinase 3; Mitogen-activated protein kinase ERK-A; MNK1; mpk1; Mtap2k; Myelin basic protein kinase; Myelin xP42 protein kinase; p38; p40; p41; p41mapk; p42; p42 MAP Kinase; P42MAPK; p42-MAPK; p44; p44 MAP kinase; p44erk1; p44-ERK1; p44mapk; p44-MAPK; pERK; p-ERK; phospho-ERK; pMapK; pp42/MAP kinase; Prkm1; PRKM2; Prkm3; protein kinase; Protein rolled; protein tyrosine kinase ERK2; RE08694p; RL; rl/ERK; rl/MAPK; rll; rl-PA; rl-PC; rl-PD; rl-PE; rl-PG; rl-PH; rl-PI; roll; rolled; sem; sevenmaker; SR2-1; Su(Raf)2B; wu:fi06b09; XELAEV_18010534mg; xp42; zERK1; zERK2 |
| Show More |
Frequently Asked Questions (FAQs)
Antibodies are tested and validated in a variety of ways. First, we verify that in a panel of cells in which different pathways have been induced, we see phosphorylation specific staining only in the cells in which the specific pathway of interest has been activated. Second, we verify that phosphorylation specific staining is observed only in cell types in which the protein is expressed and not in cell types in which the protein is not expressed. Third, whenever possible, western immunoblotting is used to confirm the presence of a band(s) of the appropriate size(s) in stimulated/treated cells (and not in unstimulated/untreated cells, as appropriate).
We have data demonstrating that fixed cells stored in methanol are stable at -20 degrees C or at -80 degrees C for several weeks. We do not recommend storing fixed cells in eBioscience Foxp3/Transcription Factor Buffer. However, cells fixed with eBioscience Foxp3/Transcription Factor Buffer or eBioscience Intracellular (IC) fixation buffer can be stored in eBioscience IC fixation buffer for up to 3 days at 4 degrees C in the dark.
Note: Please be aware that higher compensation values may be seen with tandem dyes if any other fixative is used apart from eBioscience IC fixation buffer, for 3-day storage.
Each antibody has been tested in three different buffer systems: IC fixation and permeabilization, Foxp3/Transcription Factor Buffer, and IC fixation Buffer/Methanol. The recommended buffer system(s) will be noted on the Technical Data Sheet for the specific antibody.
Because methanol can destroy the epitope recognized by some antibodies, ideally surface staining would be performed at the beginning of the protocol with a methanol-resistant fluorochrome (like eFluor 450, FITC, and eFluor 660).
Please recognize that surface staining before stimulation can have undesired effects due to activation of the cell caused by antibody binding. We recommend staining after stimulation/treatment, fixation, and methanol treatment.
In general, you can use other companies' buffer systems provided that their buffers are of a similar composition as the buffers recommended. Be aware that results will vary depending upon the buffer system used. eBioscience antibodies have been optimized for use in eBioscience buffers and we have not tested all of our antibodies in other buffer systems. Thus, we highly recommend using our optimized protocol and buffer systems.
For Research Use Only.
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.